Folic Acid News and Research

RSS

Folic acid is a B vitamin. It helps the body make healthy new cells. Everyone needs folic acid. For women who may get pregnant, it is really important. When a woman has enough folic acid in her body before and during pregnancy, it can prevent major birth defects of her baby's brain or spine.

Foods with folic acid in them include leafy green vegetables, fruits, dried beans, peas and nuts. Enriched breads, cereals and other grain products also contain folic acid. If you don't get enough folic acid from the foods you eat, you can also take it as a dietary supplement.

Study shows risky knowledge gaps, deficits in dietary supplements among pregnant women

Research conducted by the Chair of Nutritional Medicine at the Technische Universitaet Muenchen indicates there are knowledge gaps: According to this study, pregnant women often start taking sensible dietary supplements too late or not at all. At the same time, other micronutrients are unwittingly overdosed whose effects during pregnancy have not yet been studied.

19 Jan 2011

Beer cheers for health: Study look at beer, Mediterranean diet and heart

A new study shows that people who drink moderate amounts of beer, ale or lager reduce their risk of high blood pressure and diabetes. The study involved 1,249 volunteers over 57 years old who combined a Mediterranean diet (fish, olive oil, and fruits and vegetables) with exercise and up to a pint of beer a day. People, who drank beer in moderation, had a lower body fat content.

17 Jan 2011

Close pregnancies increase autism risk: Study

According to a new study published in the February issue of Paediatrics, children born within one year of an older sibling may be three times more likely to be diagnosed with autism.

10 Jan 2011

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration (FDA) for a Ready-to-Use formulation of FUSILEV (levoleucovorin) for Injection.

5 Jan 2011

People with high RBC folate levels more likely to have two tumor-suppressing genes

People with higher levels of folate in their red blood cells were more likely to have two tumor-suppressing genes shut down by methylation, a chemical off switch for genes, researchers report in the December issue of Cancer Prevention Research.

22 Dec 2010

Maternal prenatal supplements boost child's intellectual and motor function

In an area where iron deficiency is prevalent, children of mothers in rural Nepal who received prenatal iron, folic acid and vitamin A supplementation performed better on measures of intellectual and motor functioning compared to offspring of mothers who received vitamin A alone, according to a study in the December 22/29 issue of JAMA.

22 Dec 2010

Prenatal iron-folic acid supplementation increases intellectual, motor function in children

In developing countries where iron deficiency is prevalent, prenatal iron-folic acid supplementation increased offspring intellectual and motor functioning during school age, according to researchers from the Johns Hopkins Bloomberg School of Public Health.

22 Dec 2010

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

$Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL$

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics, Inc. today reported new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

$Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010$

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Allos Therapeutics, Inc. today reported updated results from the Company's Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma. Data were presented at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

New findings on folic acid supplementation reveal causes of low birth weight

Groundbreaking work by a team of UK scientists has identified, for the first time, a link between changes in the DNA of newborn babies, folic acid supplementation during pregnancy, and birth weight.

1 Dec 2010

Age-related hearing loss associated with low serum levels of folic acid in the elderly

Age-related hearing loss (ARHL), one of the four most prevalent chronic conditions in the elderly, is associated with low serum levels of folic acid, according to new research published in the December 2010 issue of Otolaryngology - Head and Neck Surgery.

1 Dec 2010

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the complete response regarding its supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

29 Nov 2010

Doctors treating female epilepsy patients have to consider specific hormonal situation

Doctors treating female epilepsy patients have to take account of the specific hormonal situation in women. Such an approach can often reduce the limitations imposed by the disease. This is the conclusion reached by Sabine Weil of Munich University and her co-authors in the latest issue of Deutsches Ärzteblatt International

25 Nov 2010

Further studies needed over use of Proton-Pump Inhibitors in early pregnancy

Despite the reassurances of Pasternak and Hviid in their study, "Use of Proton-Pump Inhibitors (PPI) in Early Pregnancy and the Risk of Birth Defects," featured in the Nov. 24 issue of the New England Journal of Medicine, an epidemiologist from Boston University School of Medicine (BUSM) believes that further studies are needed.

25 Nov 2010

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.

20 Nov 2010

Micronutrient Initiative receives $75 million to expand innovative nutrition programming

Minister of International Cooperation, Beverley Oda, has announced $75 million in new funding for the work of the Micronutrient Initiative to expand innovative nutrition programming and strengthen African health systems. The investment will be spread over five years and is expected to benefit 4 million pregnant women and 14 million children under the age of five - particularly in sub-Saharan Africa.

2 Nov 2010

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

1 Nov 2010

B-complex vitamins slow down mild cognitive impairment

Large doses of B-complex vitamins could reduce the rate of brain shrinkage by half in elderly people with memory problems and slow the progression of dementia.

25 Oct 2010

Folic Acid News and Research

Further Reading

Study shows risky knowledge gaps, deficits in dietary supplements among pregnant women

Beer cheers for health: Study look at beer, Mediterranean diet and heart

Close pregnancies increase autism risk: Study

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

People with high RBC folate levels more likely to have two tumor-suppressing genes

Maternal prenatal supplements boost child's intellectual and motor function

Prenatal iron-folic acid supplementation increases intellectual, motor function in children

Bayer's SAFYRAL oral contraceptive receives FDA approval

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

New findings on folic acid supplementation reveal causes of low birth weight

Age-related hearing loss associated with low serum levels of folic acid in the elderly

Spectrum's FUSILEV sNDA accepted by FDA for review

Doctors treating female epilepsy patients have to consider specific hormonal situation

Further studies needed over use of Proton-Pump Inhibitors in early pregnancy

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Micronutrient Initiative receives $75 million to expand innovative nutrition programming

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

B-complex vitamins slow down mild cognitive impairment

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News